

Q-linea's Q3 interim report will be published on October 31, 2022

Due to yesterday's news that Q-linea is changing the distribution of ASTar, Q-linea will publish the interim report for quarter 3, 2022 earlier than previously announced. It will be published on Monday, October 31, 2022, at 07:30 (CET).

Q-linea invites to an audiocast with conference call (in English) for investors, analysts, and media on October 31, 2022, at 13:00 – 14:00 (CET).

Jonas Jarvius, CEO, and Anders Lundin, CFO/IR, will present Q-linea and comment on the interim report, followed by a Q&A session.

To participate, please call any of the following phone numbers from:

SE: + 46 850 558 352

UK: + 44 333 300 9261

US: + 1 646 722 4903

Webcast: <https://ir.financialhearings.com/q-linea-q3-2022>

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

Jonas.Jarvius@qlinea.com

+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB

Anders.Lundin@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

[Q-linea's Q3 interim report will be published on October 31, 2022](#)